Abstract
Introduction Multidomain lifestyle interventions may slow down cognitive decline and dementia, but the brain mechanisms underlying these effects remain unclear. We investigated brain, inflammation, cardiometabolic, and gut health changes associated with a six-month multidomain lifestyle intervention in Dutch older adults at risk for cognitive decline and dementia.
Method Participants aged 60–75 years with ≥2 lifestyle-modifiable cardiovascular risk factors (e.g., BMI ≥25, physical inactivity) were recruited and randomised in a 1:1 ratio to a high-intensity intervention or active control group using stratified (2,4) block-randomisation. The multidomain lifestyle intervention included five lifestyle domains (diet, physical activity, stress management and mindfulness, cognitive training, and sleep). Primary outcomes were changes in cerebral perfusion levels, brain activity during working memory, working memory performance, inflammation profile, and microbiota diversity. Secondary outcomes included lifestyle factors and markers of neuroimaging, brain health, cardiovascular and gut health, and cognitive functioning. The effects of the lifestyle intervention were investigated using linear mixed-effect models.
Results A total of 102 participants were randomised into the intervention (n=53) or active control group (n=49), of which 86 participants completed the six-month multidomain lifestyle intervention. Baseline characteristics were similar between the groups. The intervention resulted in improved diet and sleep scores in the intervention group compared to the active control group (Beta 1.67, 95% CI 0.61;2.73, PFDR=0.01, and Beta −1.80, 95% CI −2.79;-0.81, PFDR=0.005, respectively). Within the intervention group, favourable reductions in lifestyle-modifiable cardiovascular risk factors, such as BMI and blood pressure, were observed, but these were not significantly different from changes in the active control group. The intervention did not result in significant changes over time between the intervention and control group in other primary and secondary outcomes.
Conclusion The HELI multidomain lifestyle was able to reduce lifestyle-modifiable cardiovascular risk factors associated with dementia, although not significant compared to the active control group. We did not observe significant intervention effects on brain, cardiometabolic, inflammatory, and gut health outcomes. These results emphasize the complexity of exploring the role of lifestyle on neurobiological brain mechanisms associated with maintaining optimal cognitive functioning in aging and their underlying peripheral (to central) mechanisms.
Clinical Trial Registration Information The HELI study was approved by an accredited Dutch national research ethics committee, the Medical Research Ethics Committee (MREC) Oost-Nederland (file number NL78263.091.21). This study is registered with ClinicalTrials.gov (Trial ID NCT05777863).
Competing Interest Statement
JAHRC: PI in the ABOARD consortium. Local PI in EVOKE trial (NovoNordisk); consultancy or speaker for Eisai, Lilly, BMS, Novo Nordisk; Editor for JCBFM; SAB member for Alzheimer Nederland; Dutch National Guidelines committee member for dementia. IV: consultancy for Neurogen Biomarking, received research support for public-private partnerships (TKI, Health~Holland) with Olink, Quanterix, Labonovum and Neurogen Biomarking, and performs contract research with Roche Diagnostics; all paid directly to her institution. All other authors declare no conflict of interest.
Clinical Trial
NCT05777863
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical Research Ethics Committee (MREC) Oost-Nederland (file number NL78263.091.21) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data produced in the present study are available upon reasonable request to the authors.
Funder Information Declared
